Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System

3,4-Methylenedioxymethamphetamine (MDMA) is being investigated in controlled clinical trials for use as an adjunct medication treatment for post-traumatic stress disorder. MDMA is metabolized by N-demethylation, primarily by CYP2D6, to its main inactive metabolite, 4-hydroxy-3-methoxymethamphetamine...

Descripció completa

Dades bibliogràfiques

Autors principals:	Tigran Makunts, Ruben Abagyan
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-06-01
Col·lecció:	Frontiers in Psychiatry
Matèries:	DILI (drug-induced liver injury) MDMA DDI (drug-drug interaction) FAERS adverse events MDMA (3,4-methylenedioxymethamphetamine)
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1414622/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!